| Date & Time | 20-21 January 2026 |
|---|---|
| Location | Online |
This conference will explore a seemingly paradoxical approach to cancer therapy: the deliberate hyper-activation of cancer-relevant signalling pathways.
Accumulating evidence suggests that this leads to cell death caused by a further activation of cellular stress responses. Such an approach could revolutionise treatment strategies, which often cannot abate the return of resistance in advanced cancers caused by secondary mutations reactivating previously inhibited pathways.
Join on 20 and 21 January 2026 to learn the latest science in this field from our panel of globally renowned experts. They will teach you about ways to hyperactivate oncogenic signalling and how the vulnerabilities associated with this state can be identified. In doing so, you’ll gain a fundamentally different perspective on ways to treat cancer.
Deadlines: Abstract submission deadline: 17 November 2025 Registration deadline: 15 December 2025
Contact Person: Chris Iliffe at christopher.iliffe@eacr.org.
